XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Restructuring Expenses
9 Months Ended
Sep. 30, 2021
Restructuring and Related Activities [Abstract]  
Restructuring Expenses Restructuring Expenses
During 2020, the Company announced a company-wide organizational realignment initiative in order to more effectively align its organizational infrastructure and operations with the strategic vision of the autonomous pharmacy. During the second quarter of 2020, the Company also initiated a restructuring plan to help mitigate the adverse impact of the COVID-19 pandemic on its business and financial results. During the nine months ended September 30, 2020, the Company incurred $10.0 million of employee severance costs and related expenses.
    In the first quarter of 2021, the Company continued its organizational realignment initiative, incurring $2.0 million of employee severance costs and related expenses. The Company did not incur any additional restructuring expenses during the three months ended September 30, 2021.
The following table summarizes the total restructuring expense recognized in the Company’s Condensed Consolidated Statements of Operations for the nine months ended September 30, 2021 and 2020:
Nine Months Ended September 30,
20212020
(In thousands)
Cost of product and service revenues$389 $2,564 
Research and development105 3,716 
Selling, general, and administrative1,526 3,681 
Total restructuring expense$2,020 $9,961